Pablo
García Pavía
Publicacións nas que colabora con Pablo García Pavía (42)
2024
-
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
The New England journal of medicine, Vol. 390, Núm. 20, pp. 1849-1861
-
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993
-
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
Journal of Cardiac Failure
-
Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives
Journal of the American College of Cardiology, Vol. 83, Núm. 17, pp. 1640-1651
-
Phenotype and Clinical Outcomes in Desmin-Related Arrhythmogenic Cardiomyopathy
JACC: Clinical Electrophysiology, Vol. 10, Núm. 6, pp. 1178-1190
-
Pregnancy in women with dilated cardiomyopathy genetic variants
Revista Espanola de Cardiologia
-
Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy
ESC Heart Failure
-
REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNARelated Dilated Cardiomyopathy
Circulation: Heart Failure, Vol. 17, Núm. 7, pp. e011548
2023
-
2023 ESC Guidelines for the management of cardiomyopathies
European heart journal, Vol. 44, Núm. 37, pp. 3503-3626
-
Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry
European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53
-
Emery-Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure
European Heart Journal, Vol. 44, Núm. 48, pp. 5064-5073
-
Linee guida ESC 2023 per il trattamento delle cardiomiopatie elaborate dalla task force per il trattamento delle cardiomiopatie della Società Europea di Cardiologia (ESC)
Giornale italiano di cardiologia (2006), Vol. 24, Núm. 11, pp. 1e-127e
-
Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 34-45
-
Phenotype and clinical outcomes of Glu89Lys hereditary transthyretin amyloidosis: a new endemic variant in Spain
Amyloid, Vol. 30, Núm. 2, pp. 199-207
-
Risks of Ventricular Arrhythmia and Heart Failure in Carriers of RBM20 Variants
Circulation: Genomic and Precision Medicine, Vol. 16, Núm. 5, pp. 434-441
2022
-
Combination of late gadolinium enhancement and genotype improves prediction of prognosis in non-ischaemic dilated cardiomyopathy
European Journal of Heart Failure, Vol. 24, Núm. 7, pp. 1183-1196
-
Erratum: Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator (European Heart Journal (2022) (ehac235) DOI: 10.1093/eurheartj/ehac235)
European Heart Journal
-
Genotype-phenotype correlations in hypertrophic cardiomyopathy: a multicenter study in Portugal and Spain of the TPM1 p.Arg21Leu variant
Revista Espanola de Cardiologia, Vol. 75, Núm. 3, pp. 242-250
-
Impact of SARS-Cov-2 infection in patients with hypertrophic cardiomyopathy: results of an international multicentre registry
ESC Heart Failure, Vol. 9, Núm. 4, pp. 2189-2198
-
Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator
European heart journal, Vol. 43, Núm. 32, pp. 3053-3067